Welcome to our dedicated page for ZOETIS news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on ZOETIS stock.
Zoetis Inc. (symbol: ZTS) is a leading American pharmaceutical company and the world's largest producer of medicines and vaccinations for pets and livestock. Originally a subsidiary of Pfizer, Zoetis became an independent company following Pfizer’s spinoff of its 83% interest. Zoetis specializes in a wide range of products including anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals.
The company's revenue is split between production animals (cattle, pigs, poultry, etc.), which contribute approximately 35%, and companion animals (dogs, horses, cats), which account for nearly 65%. In the U.S., Zoetis' business is predominantly focused on companion animals, while its international operations have a slight inclination towards production animals. As an industry leader, Zoetis holds the largest market share and continues to lead in innovation and product development for animal health.
Recent achievements include the launch of new vaccines and diagnostic tools aimed at improving animal health and productivity. Financially, Zoetis remains robust with consistent revenue growth and strategic partnerships to expand its market reach. Current projects include advancing their R&D pipeline to develop next-generation animal health solutions and expanding their global footprint through acquisitions and collaborations.
Stay updated with the latest performance metrics, developments, and events related to Zoetis Inc. to make informed investment decisions.
Zoetis (NYSE:ZTS) has announced major leadership changes, including the appointment of Jamie Brannan as Chief Commercial Officer in a newly created role overseeing all commercial markets globally. The restructuring aims to accelerate long-term growth and optimize global operations. Additional changes include Wafaa Mamilli's planned departure in early 2025, with Keith Sarbaugh promoted to EVP and Chief Digital & Technology Officer. Ester Banque will transition out of her role as EVP and President of U.S. Operations, with Jared Shriver promoted to President, U.S. Operations.
Zoetis (NYSE:ZTS) has announced its participation in the Jefferies London Healthcare Conference scheduled for Wednesday, November 20, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and engage with analysts at 3:00 p.m. GMT. The session will be accessible through a live audio webcast on the company's investor relations website, with a replay available afterward.
Zoetis (NYSE:ZTS) reported strong Q3 2024 results with revenue of $2.4 billion, up 11% year-over-year, and net income of $682 million ($1.50 per diluted share), increasing 14%. The company achieved 14% operational revenue growth, with U.S. revenue up 15% to $1.3 billion and International revenue growing 13% operationally to $1.0 billion. Companion animal products showed 15% global operational growth, while livestock products grew 11%. Based on strong performance, Zoetis raised its full-year 2024 guidance, projecting revenue between $9.200-$9.300 billion (10-11% operational growth) and adjusted EPS of $5.86-$5.92.
Phibro Animal Health (PAHC) has completed the acquisition of Zoetis' medicated feed additive portfolio and certain water-soluble products. The acquisition includes 37+ product lines across approximately 80 countries, six manufacturing sites in the U.S., Italy and China, and a team of over 300 employees. The portfolio is expected to enhance Phibro's profitability, EBITDA margin, and Adjusted Earnings Per Share. The deal expands Phibro's species and product portfolios across cattle, swine, and poultry sectors, complementing their existing lineup of vaccines, nutritional specialties, and mineral nutrition.
Zoetis Inc. (NYSE:ZTS), a leading animal health company, has announced its fourth quarter 2024 dividend. The Board of Directors has declared a dividend of $0.432 per share. This dividend will be paid on Tuesday, December 3, 2024, to shareholders of record as of the close of business on Thursday, October 31, 2024. This announcement demonstrates Zoetis' commitment to returning value to its shareholders through regular dividend payments.
Zoetis and Danone have announced a strategic partnership to drive sustainable practices in dairy farming through genetic innovation. The collaboration aims to leverage Zoetis' genetic technologies globally, focusing on animal well-being, reducing environmental impact, and promoting long-term resilience in dairy farming.
Zoetis, as Danone's preferred provider for genetic testing on dairy farms, will utilize its Dairy Wellness Profit Index® (DWP$®) from CLARIFIDE® Plus. This multi-trait animal ranking selection index helps estimate the potential lifetime profit of Holstein and Jersey cattle, incorporating critical wellness traits, production, fertility, and other factors.
The partnership aims to improve environmental, resource, and operational sustainability outcomes in dairy farming. Recent studies have shown potential benefits for sustainability, methane reduction, farm profitability, and animal welfare through genetic improvements.
Zoetis Inc. (NYSE:ZTS), a leading animal health company, has announced it will host a webcast and conference call on Monday, November 4, 2024, at 8:30 a.m. (ET) to discuss its third quarter 2024 financial results. The event will feature CEO Kristin Peck and CFO Wetteny Joseph, who will review the company's performance and address questions from financial analysts.
Investors and the public can access the live webcast through the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration information is now available, and a replay of the webcast will be accessible on the same day.
Zoetis Inc. (NYSE:ZTS), a leading animal health company, is set to participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. The company will be represented by CEO Kristin Peck and CFO Wetteny Joseph, who will engage in a Q&A session with analysts at 1:05 p.m. ET.
Investors and interested parties can access a live audio webcast of the session through the Zoetis investor relations website. A replay of the event will also be made available on the same platform after the conference concludes. This participation underscores Zoetis' commitment to engaging with the financial community and providing insights into its business strategies and market position.
Zoetis Inc. (NYSE:ZTS) reported strong Q2 2024 results, with revenue of $2.4 billion, up 8% (11% operational growth). Net income was $624 million ($1.37 per diluted share), down 7% and 6% respectively. Adjusted net income reached $711 million ($1.56 per diluted share), up 9% and 11% on a reported basis, and 18% and 20% operationally.
The company saw impressive growth in both U.S. (12%) and International (10% operational) segments, with strong performance in companion animal and livestock portfolios. Key drivers included osteoarthritis pain products, Simparica Trio, and dermatology offerings.
Zoetis raised its full-year 2024 guidance, projecting revenue between $9.100-$9.250 billion (9-11% operational growth) and adjusted diluted EPS of $5.78-$5.88.
Zoetis Inc. (NYSE:ZTS) has announced a $6 billion multi-year share repurchase program, approved by its Board of Directors. This program, the company's largest to date, is expected to run for up to four years and can be cancelled at any time. The announcement reflects Zoetis' strong performance, positive long-term outlook, and commitment to returning capital to shareholders.
Wetteny Joseph, Executive VP and CFO, emphasized that Zoetis remains an attractive investment opportunity due to its consistent performance and business outlook. The company's previous $3.5 billion share repurchase program, approved in December 2021, is anticipated to be completed in 2024.
FAQ
What is the current stock price of ZOETIS (ZTS)?
What is the market cap of ZOETIS (ZTS)?
What does Zoetis Inc. specialize in?
Is Zoetis Inc. still part of Pfizer?
What percentage of Zoetis' revenue comes from companion animals?
Which segment contributes more to Zoetis' U.S. business?
How does Zoetis' international business differ from its U.S. business?
What recent achievements has Zoetis Inc. accomplished?
What are Zoetis' current projects?
What is Zoetis' market position in the industry?
Does Zoetis have any strategic partnerships?
Where can I find the latest updates on Zoetis Inc.?
